Overview
Quantitative proteomics aims to measure changes in protein abundance across different biological conditions. Unlike qualitative identification, which merely establishes the presence of a protein, quantification reveals how the proteome responds to stimuli, disease, or treatment. Two broad strategies dominate the field: label-based methods that introduce stable isotope tags into proteins or peptides, and label-free methods that infer abundance from spectral counts or ion intensities. Each approach carries trade-offs between accuracy, multiplexing capacity, cost, and experimental complexity, making the choice of method highly dependent on the biological question being asked.
Methods
Stable isotope labeling techniques include SILAC (metabolic labeling in cell culture), TMT and iTRAQ (isobaric tags for relative and absolute quantification), and dimethyl labeling. These introduce defined mass shifts that the mass spectrometer can distinguish, allowing multiplexed analysis of up to 16 samples in a single run. Label-free quantification uses either the number of identified spectra (spectral counting) or the extracted ion chromatogram area of each peptide (MS1 intensity). Data-independent acquisition (DIA) methods such as SWATH-MS combine deep proteome coverage with quantitative precision across large sample cohorts.
Practical Protocol
A SILAC-based quantitative proteomics experiment begins with metabolic labeling. Cells are cultured in either “light” (Arg-0, Lys-0) or “heavy” (Arg-10, Lys-8) medium for at least five cell doublings to achieve complete incorporation. Light and heavy cells are subjected to different conditions, for example, inhibitor-treated versus vehicle control. After lysis, proteins are combined in a 1:1 ratio based on total protein concentration, digested with trypsin, and fractionated by basic reverse-phase HPLC into 12–24 fractions. Each fraction is analyzed by LC-MS/MS on a high-resolution mass spectrometer. The instrument detects pairs of peptide peaks separated by the mass shift introduced by the heavy labels. Quantification occurs at the MS1 level: the software extracts ion chromatograms for each peptide pair and calculates the heavy-to-light ratio. MaxQuant processes the raw files and the resulting protein ratios are normalized by centering the median log2 ratio to zero, correcting for minor mixing errors. A two-sample t-test or ANOVA with Benjamini-Hochberg correction identifies significantly changing proteins. For TMT-based experiments, labeling occurs at the peptide level after digestion, and quantification uses reporter ion intensities in MS/MS spectra, enabling multiplexed comparison of up to 16 samples simultaneously. In a landmark application, TMT-based quantitative proteomics quantified 10,000 proteins across 10 breast cancer cell lines, revealing coordinated regulation of metabolic pathways linked to oncogenic signaling. SILAC has been used to profile the tyrosine phosphoproteome response to imatinib treatment in chronic myeloid leukemia cells, identifying both target engagement and mechanisms of drug resistance.
Applications
Quantitative proteomics is widely applied in biomarker discovery, comparing protein levels between healthy and diseased tissues to identify diagnostic or prognostic signatures. In drug development, it profiles target engagement and off-target effects. The integration of quantitative data with ELISA and Western blot validation ensures robustness. Methods such as mass spectrometry-based quantification complement traditional gel-based approaches like SDS-PAGE and capillary gel electrophoresis (CGE), providing deeper coverage and higher throughput.
